Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 3/20 | 0.33 |
| ▸ | SKP1 | P63208 | 3/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257450 | 0.86 | ALDH1A1 (0.45) | MAPTALDH1A1BRPF1RAB9AHDAC3 | |
| SCHEMBL30976536 | 0.85 | GAA (0.51) | MAPTALDH1A1GAANPC1HTT | |
| SCHEMBL4672167 | 0.85 | GAA (0.51) | MAPTALDH1A1GAANPC1HTT | |
| SCHEMBL4374612 | 0.80 | TACR1 (0.43) | MAPTALDH1A1NPC1RAB9ADGAT1 | |
| SCHEMBL4377962 | 0.76 | MAPT (0.68) | MAPTALDH1A1NPC1RAB9ADGAT1 | |
| SCHEMBL12131479 | 0.73 | RAB9A (0.42) | MAPTALDH1A1GAANPC1RAB9A | |
| SCHEMBL13686268 | 0.72 | RAB9A (0.46) | MAPTALDH1A1BRPF1NPC1RAB9A | |
| SCHEMBL6387444 | 0.72 | TRPV1 (0.38) | BRPF1GSK3BCKS1BSKP1SKP2 | |
| SCHEMBL4262849 | 0.72 | TACR1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL14005069 | 0.72 | RAB9A (0.40) | MAPTALDH1A1NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414525-B1 | 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-¬6-(1,1-DIOXO-1.LAMBDA.6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL -N-METHYL-ISOBUTYRAMIDE | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| EP-1385577-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| US-6849624-B2 | Aromatic and heteroaromatic substituted amides | HOFFMANN-LA ROCHE INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1414525-A2 | 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1.LAMBDA.6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-06 | — | — | EP | disclosed |
| EP-1385577-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. Hoffman-la Roche AG (CH) | 2004-02-04 | — | — | EP | disclosed |
| US-20030064983-A1 | Aromatic and heteroaromatic substituted amides | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-04-03 | — | — | US | disclosed |
| WO-2003011860-A2 | 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-13 | — | — | WO | disclosed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064983-A1 | Aromatic and heteroaromatic substituted amides | OPRK1, HRH4, OPRL1 | MAPT 173/4885ALDH1A1 2029/4885BRPF1 2782/4885 |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | MAPT 2922/4885ALDH1A1 464/4885BRPF1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.